

VERTEX PHARMACEUTICALS INC / MA  
Form 8-K  
February 17, 2004

[QuickLinks](#) -- Click here to rapidly navigate through this document

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): February 13, 2004

---

**VERTEX PHARMACEUTICALS INCORPORATED**

(Exact name of registrant as specified in its charter)

**MASSACHUSETTS**  
(State or Other Jurisdiction  
of incorporation)

**000-19319**  
(Commission  
File Number)

**04-3039129**  
(IRS Employer  
Identification No.)

**130 Waverly Street Cambridge, Massachusetts 02139**  
(Address of principal executive offices) (Zip Code)

**(617) 444-6100**

Registrant's telephone number, including area code:

---

---

---

**ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.**

(c) Exhibits

99.1 Press Release of Vertex Pharmaceuticals Incorporated dated February 13, 2004.

**ITEM 9. REGULATION FD.**

The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

On February 13, 2004, Vertex Pharmaceuticals Incorporated issued a press release announcing that it had completed the exchange of approximately \$153 million in aggregate principal amount of its 5% Convertible Subordinated Notes due 2007 for approximately \$153 million

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 8-K

in aggregate principal amount of newly issued 5.75% Convertible Senior Subordinated Notes due 2011. The press release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference in its entirety.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VERTEX PHARMACEUTICALS  
INCORPORATED  
(Registrant)

Date: February 13, 2004

/s/ IAN F. SMITH

---

Ian F. Smith  
*Senior Vice President and Chief Financial Officer*

---

**EXHIBIT INDEX**

The following exhibit is furnished as part of this current report on Form 8-K:

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of Vertex Pharmaceuticals Incorporated dated February 13, 2004

---

QuickLinks

SIGNATURES

EXHIBIT INDEX